Literature DB >> 24802758

A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism.

Jordan D Dimitrov1, Cyril Planchais2, Tobias Scheel3, Delphine Ohayon2, Stephane Mesnage4, Claudia Berek3, Srinivas V Kaveri2, Sébastien Lacroix-Desmazes2.   

Abstract

Polyreactive antibodies play an important role for neutralization of human immunodeficiency virus (HIV). In addition to intrinsic polyreactive antibodies, the immune system of healthy individuals contains antibodies with cryptic polyreactivity. These antibodies acquire promiscuous antigen binding potential post-translationally, after exposure to various redox-active substances such as reactive oxygen species, iron ions, and heme. Here, we characterized the interaction of a prototypic human antibody that acquires binding potential to glycoprotein (gp) 120 after exposure to heme. The kinetic and thermodynamic analyses of interaction of the polyreactive antibody with distinct clades of gp120 demonstrated that the antigen-binding promiscuity of the antibody compensates for the molecular heterogeneity of the target antigen. Thus, the polyreactive antibody recognized divergent gp120 clades with similar values of the binding kinetics and quantitatively identical changes in the activation thermodynamic parameters. Moreover, this antibody utilized the same type of noncovalent forces for formation of complexes with gp120. In contrast, HIV-1-neutralizing antibodies isolated from HIV-1-infected individuals, F425 B4a1 and b12, demonstrated different binding behavior upon interaction with distinct variants of gp120. This study contributes to a better understanding of the physiological role and binding mechanism of antibodies with cryptic polyreactivity. Moreover, this study might be of relevance for understanding the basic aspects of HIV-1 interaction with human antibodies.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Antibody; Antibody Polyreactivity; HIV-1 Protease; Heme; Protein-Protein Interaction; Thermodynamics; gp120

Mesh:

Substances:

Year:  2014        PMID: 24802758      PMCID: PMC4067210          DOI: 10.1074/jbc.M114.556266

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  73 in total

1.  Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site.

Authors:  V Manivel; N C Sahoo; D M Salunke; K V Rao
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

2.  Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions.

Authors:  Jordan D Dimitrov; Lubka T Roumenina; Virjinia R Doltchinkova; Nikolina M Mihaylova; Sebastien Lacroix-Desmazes; Srinivas V Kaveri; Tchavdar L Vassilev
Journal:  J Biol Chem       Date:  2007-07-18       Impact factor: 5.157

3.  Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases.

Authors:  U Muller-Eberhard; J Javid; H H Liem; A Hanstein; M Hanna
Journal:  Blood       Date:  1968-11       Impact factor: 22.113

Review 4.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

5.  V-region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis.

Authors:  Tobias Scheel; Angelika Gursche; Josef Zacher; Thomas Häupl; Claudia Berek
Journal:  Arthritis Rheum       Date:  2011-01

6.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.

Authors:  Hugo Mouquet; Johannes F Scheid; Markus J Zoller; Michelle Krogsgaard; Rene G Ott; Shetha Shukair; Maxim N Artyomov; John Pietzsch; Mark Connors; Florencia Pereyra; Bruce D Walker; David D Ho; Patrick C Wilson; Michael S Seaman; Herman N Eisen; Arup K Chakraborty; Thomas J Hope; Jeffrey V Ravetch; Hedda Wardemann; Michel C Nussenzweig
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

7.  Few and far between: how HIV may be evading antibody avidity.

Authors:  Joshua S Klein; Pamela J Bjorkman
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

8.  The nature of the autoimmune antibody repertoire in human immunodeficiency virus type 1 infection.

Authors:  H J Ditzel; S M Barbas; C F Barbas; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

9.  Inhibition of human immunodeficiency virus-1 reverse transcriptase by heme and synthetic heme analogs.

Authors:  R Staudinger; N G Abraham; R D Levere; A Kappas
Journal:  Proc Assoc Am Physicians       Date:  1996-01

10.  Hemin activation ameliorates HIV-1 infection via heme oxygenase-1 induction.

Authors:  Krishnakumar Devadas; Subhash Dhawan
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

View more
  6 in total

1.  Prevalence and gene characteristics of antibodies with cofactor-induced HIV-1 specificity.

Authors:  Maxime Lecerf; Tobias Scheel; Anastas D Pashov; Annaelle Jarossay; Delphine Ohayon; Cyril Planchais; Stephane Mesnage; Claudia Berek; Srinivas V Kaveri; Sébastien Lacroix-Desmazes; Jordan D Dimitrov
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

2.  Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival.

Authors:  Iglika Djoumerska-Alexieva; Lubka T Roumenina; Tsvetanka Stefanova; Tchavdar Vassilev; Jordan D Dimitrov
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

Review 3.  Breaking the law: unconventional strategies for antibody diversification.

Authors:  Alexia Kanyavuz; Annaelle Marey-Jarossay; Sébastien Lacroix-Desmazes; Jordan D Dimitrov
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

4.  Aromatic Guanylhydrazones for the Control of Heme-Induced Antibody Polyreactivity.

Authors:  Nina Božinović; Vladimir Ajdačić; Jelena Lazic; Maxime Lecerf; Victoria Daventure; Jasmina Nikodinovic-Runic; Igor M Opsenica; Jordan D Dimitrov
Journal:  ACS Omega       Date:  2019-11-22

5.  Interaction of clinical-stage antibodies with heme predicts their physiochemical and binding qualities.

Authors:  Maxime Lecerf; Alexia Kanyavuz; Sofia Rossini; Jordan D Dimitrov
Journal:  Commun Biol       Date:  2021-03-23

6.  Functional Changes of Therapeutic Antibodies upon Exposure to Pro-Oxidative Agents.

Authors:  Maxime Lecerf; Robin Lacombe; Alexia Kanyavuz; Jordan D Dimitrov
Journal:  Antibodies (Basel)       Date:  2022-02-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.